Clinicopathological features of inflammatory versus noninflammatory locally advanced nonmetastatic breast cancer

Tumor Biology

Volumn 29, Issue 4, 2008, Pages 211-216

  Brouwers, B ^a   Paridaens, R ^a   Lobelle, J P ^a   Hendrickx, W ^a   Smeets, A ^a   Neven, P ^a   Weltens, C ^a   Deraedt, K ^a   Vanden Bempt, I ^a   Christiaens, M R ^a   Wildiers, H ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Breast cancer, inflammatory; Breast cancer, locally advanced; HER2

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; AXILLARY LYMPH NODE; BODY MASS; BREAST CANCER; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BREAST CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 51049103228     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000152938     Document Type: Article

References (27)

1. Walshe J, Swain S: Clinical aspects of inflammatory breast cancer. Breast Dis 2005-2006;22:35-44.
2. Hance K, Anderson W, Devesa S, et al: Trends in inflammatory breast carcinoma incidence and survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-975.
3. Anderson W, Chu K, Chang S: Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 2003;21:2254-2259.
4. Kleer C, Van Golen K, Merajver S: Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000;2:423-429.
5. Wu M, Merajver S: Molecular biology of inflammatory breast cancer: applications to diagnosis, prognosis, and therapy. Breast Dis 2005-2006;22:25-34.
6. McCarthy N, Yang X, Linnoila I, et al: Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002;8:3857-3862.
7. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al: Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004;10:7965-7971.
8. Shirakawa K, Tsuda H, Heike Y, et al: Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001;61:445-451.
9. Turpin E, Bièche I, Bertheau P, et al: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593-7597.
10. Sawaki M, Ito Y, Akiyama F, et al: High prevalence of Her-2/neu and p53 overexpression in inflammatory breast cancer. Breast Cancer 2006;13:172-178.
11. Parton M, Dowsett M, Ashley S, et al: High incidence of Her-2 positivity in inflammatory breast cancer. Breast 2004;13:97-103.
12. Aziz SA, Pervez S, Khan S, et al: Case control study of prognostic markers and disease outcome in inflammatory carcinoma breast: a unique clinical experience. Breast J 2001;7:398-404.
13. Charafe-Jauffret E, Tarpin C, Bardou VJ, et al: Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. J Pathol 2004;202:265-273.
14. Dirix L, Van Dam P, Prové A, et al: Inflammatory breast cancer: current understanding. Curr Opin Oncol 2006;18:563-571.
15. Greene F: AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
16. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al: Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in Her-2/neu overexpression in human breast carcinoma's. Histopathology 2005;46:431-441.
17. Bièche I, Lerebours F, Tozlu S, et al: Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-6795.
18. Bertucci F, Finetti P, Rougemont J, et al: Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004;64:8558-8565.
19. Bertucci F, Finetti P, Rougemont J, et al: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005;65:2170-2178
20. Van Laere S, Van der Auwera I, Van den Eynden G, et al: Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005;93:237-246.
21. Dressman HK, Hans C, Bild A, et al: Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006;12:819-826.
22. Paradiso A, Tommasi S, Brandi M, et al: Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease. Cancer 1989;64:1922-1927.
23. Dendukuri N, Khetani K, McIsaac M, et al: Testing for Her2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ 2007;176:1429-1434
24. Wolff A, Hammond M, Schwartz J, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
25. Amparo RS, Angel CD, Ana LD, et al: Inflammatory breast carcinoma: pathological or clinical entity? Breast Cancer Res Treat 2000;64:269-273.
26. Jatoi I, Chen B, Anderson W, et al: Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis. J Clin Oncol 2007;25:1683-1690.
27. Chang S, Buzdar AU, Hursting SD: Inflammatory breast cancer and body mass index. J Clin Oncol 1998;16:3731-3735.